Closing the Biotech "Valley of Death": The Infrastructure Gap Holding Back Early-Stage Biologics Programs:

"The challenge is not getting better biology. It's building a better system to carry the biology forward," says Richard van Rijnsoever.Debby Vermeer and Richard van Rijnsoever are co-founders of ExpediteBio, a Netherlands-based venture focused on accelerating antibody and protein therapeutics from discovery to first-in-human study. Debby also co-leads the biologics workstream at Oncode Accelerator, a national initiative working to accelerate cancer therapy development, e.g., by building infrastructure in the Netherlands.On the PharmaSource podcast, Debby and Richard spoke about the structural reasons biologics programs fail to reach patients, how their ASCEND framework addresses those failures, and what a more functional European biologics ecosystem could look like. Their conversation is a practical guide for biotech CEOs and CMC leaders navigating the most expensive stretch of early-stage drug development.Read more.